ES2074454T3 - Uso de antagonistas opiaceos para la preparacion de una composicion farmaceutica para el tratamiento del alcoholismo. - Google Patents

Uso de antagonistas opiaceos para la preparacion de una composicion farmaceutica para el tratamiento del alcoholismo.

Info

Publication number
ES2074454T3
ES2074454T3 ES89110688T ES89110688T ES2074454T3 ES 2074454 T3 ES2074454 T3 ES 2074454T3 ES 89110688 T ES89110688 T ES 89110688T ES 89110688 T ES89110688 T ES 89110688T ES 2074454 T3 ES2074454 T3 ES 2074454T3
Authority
ES
Spain
Prior art keywords
alcoholism
preparation
treatment
pharmaceutical composition
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89110688T
Other languages
English (en)
Inventor
John David Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alko Oy AB
Original Assignee
Alko Oy AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22763531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074454(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alko Oy AB filed Critical Alko Oy AB
Application granted granted Critical
Publication of ES2074454T3 publication Critical patent/ES2074454T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

ES DESCRITO EL USO DE ANTAGONISTA NARCOTICOS PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA SER ADMINISTRADOS SIMULTANEAMENTE O SEPARADAMENTE SECUENCIAL CON ALCOHOL EN EL TRATAMIENTO DE ALCOHOLISMO. ESAS COMPOSICIONES FARMACEUTICAS SON CAPACES DE EXTINGUIR LA RESPUESTA DE BEBER ALCOHOL DE ALCOHOLICOS DURANTE UN PERIODO CORTO DE TIEMPO RELATIVAMENTE POR TENER LOS ALCOHOLICOS QUE BEBER BEBIDAS ALCOHOLICAS REPETIDAMENTE MIENTRAS EL ANTAGONISTA NARCOTICO CONTENIDO EN DICHA COMPOSICION FARMACEUTICAMENTE BLOQUEA LOS EFECTOS DE REFUERZO POSITIVO DE ETANOL EN EL CEREBRO.
ES89110688T 1988-06-13 1989-06-13 Uso de antagonistas opiaceos para la preparacion de una composicion farmaceutica para el tratamiento del alcoholismo. Expired - Lifetime ES2074454T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/205,758 US4882335A (en) 1988-06-13 1988-06-13 Method for treating alcohol-drinking response

Publications (1)

Publication Number Publication Date
ES2074454T3 true ES2074454T3 (es) 1995-09-16

Family

ID=22763531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89110688T Expired - Lifetime ES2074454T3 (es) 1988-06-13 1989-06-13 Uso de antagonistas opiaceos para la preparacion de una composicion farmaceutica para el tratamiento del alcoholismo.

Country Status (7)

Country Link
US (1) US4882335A (es)
EP (1) EP0346830B1 (es)
AT (1) ATE122231T1 (es)
AU (1) AU609310B2 (es)
CA (1) CA1336962C (es)
DE (1) DE68922525T2 (es)
ES (1) ES2074454T3 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5013740A (en) * 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
HUP0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
EP1492506B2 (en) 2002-04-05 2016-06-29 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
ES2359977T3 (es) 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
WO2008051902A2 (en) 2006-10-20 2008-05-02 Cpd, Llc Method of restoring the incretin effect
FI20070705L (fi) 2007-09-14 2009-06-02 Biohit Oyj Asetaldehydin sitominen suussa ja mahalaukussa
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA2948144A1 (en) * 2014-05-06 2015-11-12 Purdue Pharma L.P. Benzomorphan analogs and use thereof
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
EP3474842A4 (en) * 2016-06-24 2020-01-29 Opiant Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL RELATED DISORDER
JP7312698B2 (ja) 2016-11-18 2023-07-21 オーピアント ファーマシューティカルズ， インコーポレイテッド オピオイド過剰摂取を処置するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene

Also Published As

Publication number Publication date
US4882335A (en) 1989-11-21
EP0346830B1 (en) 1995-05-10
EP0346830A2 (en) 1989-12-20
CA1336962C (en) 1995-09-12
ATE122231T1 (de) 1995-05-15
AU609310B2 (en) 1991-04-26
DE68922525D1 (de) 1995-06-14
AU3634889A (en) 1989-12-14
EP0346830A3 (en) 1991-09-25
DE68922525T2 (de) 1996-01-04

Similar Documents

Publication Publication Date Title
ES2074454T3 (es) Uso de antagonistas opiaceos para la preparacion de una composicion farmaceutica para el tratamiento del alcoholismo.
Cox et al. The effect of analgesic drugs on the release of acetylcholine from electrically stimulated guinea-pig ileum.
Schwartz et al. Regression of experimental hamster cancer by beta carotene and algae extracts
Han et al. Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous antiopioid substrates?
AU6665090A (en) Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
IL101225A0 (en) Bi-and tricyclic amino alcohol esters,their preparation and pharmaceutical compositions containing them
ATE119040T1 (de) Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
PL313075A1 (en) Heterocyclic compounds used as antagonistic substances in respect to neurokinin
YU46160B (sh) Postupak za dobijanje sterilnog rastvora za injekcije koji sadrži antraciklinske glikozide
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
DE3572807D1 (en) A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use
ZA981925B (en) A long acting injectable parasiticidal composition and the process for its preparation
CA2126680A1 (en) Novel megakaryocyte potentiator
DE59003994D1 (de) Substituierte 1,8-Naphthyridine.
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
Bhargava et al. Structure activity relationship studies with hypothalamic peptide hormones II. Effects of thyrotropin releasing hormone analogs on morphine-induced responses in mice
ATE92497T1 (de) Glucuronsaeure-derivate von opioid-antagonisten.
McKENNIS et al. Demethylation in the Metabolism of (—)-Nicotine in vivo
HUT54969A (en) Process for producing substituted biphenyl derivatives and pharmaceutical compositions containing them
CA2132007C (en) Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
RAMABADRAN Stereoselective enhancement of nociception by opioids in different strains of mice
Leander Delineation of mu-antagonist, partial kappa agonist and non-opioid agonist activity of cyclazocine using urinary output of rats
PE20010990A1 (es) Un kit que comprende como un primer componente irinotecano o una composicion que comprende irinotecano y como un segundo componente una o varias dosis de carbon
DE4041559A1 (de) Neue wirkstoffkombinationen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 346830

Country of ref document: ES